SCHEMBL716003

SCHEMBL716003

Cc1cccc2cc(C(C)NC(=O)O)c(N3CCN(CC(=O)N(C)C)CC3)nc12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.53
P2RX3 P56373 1/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 2/20 0.38
USP2 O75604 1/20 0.38
CLK1 P49759 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
FAAH O00519 1/20 0.37
ALOX15 P16050 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SOS1 Q07889 1/20 0.36
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717420 0.91 PIK3CD (0.44) PIK3CDP2RX3KDM4EALDH1A1NPC1
SCHEMBL715661 0.87 PIK3CD (0.55) PIK3CDP2RX3KDM4EALDH1A1TSHR
SCHEMBL715662 0.87 PIK3CD (0.55) PIK3CDP2RX3KDM4EALDH1A1TSHR
SCHEMBL713709 0.84 PIK3CD (0.53) PIK3CDP2RX3SOS1
SCHEMBL713708 0.84 PIK3CD (0.53) PIK3CDP2RX3SOS1
SCHEMBL716547 0.84 TDP1 (0.44) PIK3CDKDM4EALDH1A1TSHRUSP2
SCHEMBL716672 0.82 PIK3CD (0.51) PIK3CDP2RX3KDM4EALDH1A1TSHR
SCHEMBL715545 0.81 TSHR (0.41) PIK3CDKDM4EALDH1A1TSHRUSP2
SCHEMBL716017 0.77 PIK3CD (0.44) PIK3CDP2RX3KDM4ENPC1LMNA
SCHEMBL716018 0.77 PIK3CD (0.44) PIK3CDP2RX3KDM4ENPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885P2RX3 653/4885KDM4E 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.